SAO PAULO, BRAZIL — In a landmark policy shift reshaping the Latin American animal health industry, the Brazilian Ministry of Agriculture and Livestock (MAPA) has officially enacted Ordinance No. 1617.
The sweeping mandate completely prohibits the import, manufacture, marketing, and use of performance-enhancing feed additives containing antimicrobials categorized as highly critical to human or veterinary medicine.
The primary targets of the ban include virginiamycin and bacitracin—two foundational pillars of intensive livestock growth promotion in Brazil’s massive beef and poultry sectors.
Regulatory Mandate: MAPA Ordinance No. 1617
Published on April 27, 2026, by MAPA’s Secretariat of Agricultural Defense, Ordinance No. 1617 directly aligns Brazil with global antimicrobial stewardship frameworks practiced across the European Union, the United States, and Canada.
180-Day Transition Window
To prevent severe logistical blockages across feed manufacturing and livestock production networks, MAPA has structured a strict 180-day transition period from the publication date.
During this active grace period, animal health commercial operations and livestock producers are authorized to exhaust existing manufacturing inventories and sell products under current growth-promotion labels. Following the expiration of this buffer in late October 2026, all corresponding agricultural registrations will be formally canceled, and illegal use will face heavy federal enforcement.
Phibro’s Two-Pronged Strategy
As a major global supplier of high-performance feed additives—notably via its branded virginiamycin (Stafac®) and bacitracin methylenedisalicylate (BMD®) portfolios—Phibro Animal Health Corporation (Nasdaq: PAHC) is actively converting this regulatory challenge into a controlled structural transition.
Rather than exiting the region, Phibro is commercializing a defensive, multi-layered compliance strategy to maintain market share within Brazil’s premium agricultural corridors:
1. Shifting to Therapeutic Registrations
Phibro has confirmed it is in the final stages of cooperative review with MAPA to finalize brand-new, dedicated registrations for virginiamycin for strict therapeutic applications in cattle and broiler chickens.
Under this model, the compound will transition from a continuous sub-therapeutic feed additive to a targeted veterinary-directed medicine focused strictly on preventing and treating clinical conditions, such as Necrotic Enteritis in poultry and liver abscesses in feedlot cattle. These therapeutic labels are expected to secure final approval within the 180-day buffer zone.
2. The PhibroVet® Digital Ecosystem
Because the post-transition framework mandates that any remaining use of these medically important antimicrobials requires explicit, auditable oversight, Phibro is deploying its proprietary digital asset, PhibroVet®, across the Brazilian market.
The PhibroVet® software functions as an end-to-end digital prescription management platform.It allows field veterinarians to rapidly generate, authenticate, and transmit electronic prescriptions directly to commercial feed mills, while securing an auditable prescription history.This digital system minimizes compliance bottlenecks for corporate producers shifting to the new regulatory standard.
Outlook and Financial Guidance
During its global investor review, Phibro management emphasized that due to the 180-day implementation buffer, the policy shift will have highly limited impacts on its Fiscal Year 2026 financial results.
Wall Street analysts track this structural pivot as a crucial litmus test for corporate agility in animal health. By replacing open over-the-counter growth promotion with specialized prescription platforms and targeted therapeutic lines, Phibro is establishing a modern business template for multinational operations navigating global antibiotic reduction standards.
